US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks for mCRC (metastatic colorectal cancer). In this ongoing Phase I/IIa study, ISO-CC-005, Isofol has separately analyzed data from patients in the first line of treatment. The data demonstrates continuous response to treatment between week 8 and week 16. Moreover, non of the treated patients in this group had progressive disease.To date, 54 patients with mCRC have been treated in the ongoing ISO-CC-005 study. The study evaluates different doses of

Isofol to present at the 10th Annual Biotech Showcase Conference

Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief Commercial Officer Sven Erickson will present at the 10th Annual Biotech Showcase Conference, to be held during the 8-10th of January in San Francisco, USA. The event is a networking conference dedicated to providing biotechnology companies with an opportunity to meet with, investors and pharmaceutical executives, during the course of the largest annual healthcare investor conference, the 36th Annual J.P. Morgan Healthcare Conference. Sven Erickson, CCO of Isofol Medical,

Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical Oncology’s 53rd Annual Meeting 2017, taking place 2-6 June in Chicago. Isofol will present results from a study that demonstrates that there is an unmet clinical need of a superior rescue agent to be administrated after High Dose Methotrexate (HDMTX) treatment in osteosarcoma patients.The abstract describes the findings from a retrospective observational study in osteosarcoma patients, from four different countries, treated with HDMTX as part of the standardised MAP

Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of newly issued shares in the Company (the “Offering”) was substantially oversubscribed. The Offering attracted strong interest among Swedish and international investors. The listing on Nasdaq First North Premier has been successful and the trading commences today.  Anders Rabbe, Managing Director, comments:“The large interest shown in becoming a shareholder in Isofol, both from investors in Sweden, Europe and in the US, is a strong signal that Isofol’s development of Modufolin® rests

Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Isofol Medical AB (publ) (”Isofol” or the ”Company”), a clinical stage pharmaceutical company, announced on March 13, 2017, its intention launch an initial public offering and list its shares on Nasdaq First North Premier (“the Offering”). Today, the Company publishes the price and

Isofol announces its intention to list on Nasdaq First North Premier

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.For a complete press release follow the link http://isofol.se/ipo For additional information, please contact:Anders Rabbe, CEO, Isofol, Mob: +46 70 764 65 00, Email: anders.rabbe@isofolmedical.comJan-Eric Österlund, Executive Chairman of the Board, Isofol, Mob: +44 77 853 68 155,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe